Across TCGA pan-cancer cohorts, RPL22P14 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RPL22P14 data layer.
The strongest signal is observed in brain lower grade glioma (LGG), where higher RPL22P14 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPL22P14 expression acts as an unfavorable survival marker, although some lineages such as LGG and SKCM show a favorable association.
LGG, SKCM, and CESC are the cancer types where RPL22P14 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.